A-796,260

A-796,260

Legal status
Legal status	UK: Class B
Identifiers
IUPAC name [1-(2-morpholin-4-ylethyl)-1H-indol-3-yl]-(2,2,3,3-tetramethylcyclopropyl)methanone
CAS Number	895155-26-7^N
PubChem CID	11584525
ChemSpider	9759290^Y
UNII	5N69DXA53Z
ChEMBL	ChEMBL262865^Y
CompTox Dashboard (EPA)	DTXSID801010107
ECHA InfoCard	100.233.198
Chemical and physical data
Formula	C22H30N2O2
Molar mass	354.494 g·mol^−1
3D model (JSmol)	Interactive image
SMILES C4COCCN4CCn(c3ccccc13)cc1C(=O)C2C(C)(C)C2(C)C
InChI InChI=1S/C22H30N2O2/c1-21(2)20(22(21,3)4)19(25)17-15-24(18-8-6-5-7-16(17)18)10-9-23-11-13-26-14-12-23/h5-8,15,20H,9-14H2,1-4H3^Y Key:ZCFHOMLAFTWDFM-UHFFFAOYSA-N^Y
^NY (what is this?)  (verify)

A-796,260 is a drug developed by Abbott Laboratories that acts as a potent and selective cannabinoid CB₂ receptor agonist. Replacing the aromatic 3-benzoyl or 3-naphthoyl group found in most indole derived cannabinoids with the 3-tetramethylcyclopropylmethanone group, imparts significant selectivity for CB₂, and A-796,260 was found to be a highly selective CB₂ agonist with little affinity for CB₁, having a CB₂ K_i of 4.6 nM vs 945 nM at CB₁.[1] It has potent analgesic and anti-inflammatory actions in animal models, being especially effective in models of neuropathic pain, but without producing cannabis-like behavioral effects.[2]

Legal Status

As of October 2015 A-796,260 is a controlled substance in China.[3]

See also

• A-834,735
• A-836,339
• BMS-F
• JWH-200
• UR-144
• XLR-11

References

1. Frost JM, Dart MJ, Tietje KR, Garrison TR, Grayson GK, Daza AV, et al. (January 2010). "Indol-3-ylcycloalkyl ketones: effects of N1 substituted indole side chain variations on CB(2) cannabinoid receptor activity". Journal of Medicinal Chemistry. 53 (1): 295–315. doi:10.1021/jm901214q. PMID 19921781.
2. Yao BB, Hsieh GC, Frost JM, Fan Y, Garrison TR, Daza AV, et al. (January 2008). "In vitro and in vivo characterization of A-796260: a selective cannabinoid CB2 receptor agonist exhibiting analgesic activity in rodent pain models". British Journal of Pharmacology. 153 (2): 390–401. doi:10.1038/sj.bjp.0707568. PMC 2219533. PMID 17994110.
3. "关于印发《非药用类麻醉药品和精神药品列管办法》的通知" (in Chinese). China Food and Drug Administration. 27 September 2015. Archived from the original on 1 October 2015. Retrieved 1 October 2015.